IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

ott S. Graves et al.

Title HUMANIZED ANTIBODIES THAT BIND TO THE ANTIGEN BOUND BY ANTIBODY NR-LU-13 AND THEIR USE IN PRETARGETING METHODS

Docket No.:

295.061US4

Serial No.: 10/787,067

Filed:

February 25, 2004

Due Date: N/A

Examiner:

David J Blanchard

Group Art Unit: 1643

MS Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

We are transmitting herewith the following attached items (as indicated with an "X"):

 \underline{X} Return postcard.

X Supplemental Information Disclosure Statement (2 pgs.), Form 1449 (1 pg.), and copies of 3 cited documents.

If not provided for in a separate paper filed herewith, Please consider this a PETITION FOR EXTENSION OF TIME for sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

Customer Number 21186

Atty: Janet E. Embretson Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 2 Ap day of August, 2006.

Name

Signature

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

(GENERAL)

XN 10/787,067

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Scott S. Graves et al.

Examiner:

David J Blanchard

Applicant: Erial No.:

10/787,067

Group Art Unit:

1643

Filed:

February 25, 2004

Docket:

295.061US4

Title:

AUG 0 7 2006

HUMANIZED ANTIBODIES THAT BIND TO THE ANTIGEN BOUND BY

ANTIBODY NR-LU-13 AND THEIR USE IN PRETARGETING METHODS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 et. seq., the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicant requests that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Supplemental Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Supplemental Information Disclosure Statement considered.

Serial No:10/787,067

Filing Date: February 25, 2004

Title: HUMANIZED ANTIBODIES THAT BIND TO THE ANTIGEN BOUND BY ANTIBODY NR-LU-13 AND THEIR USE IN

PRETARGETING METHODS

Pursuant to 37 C.F.R. 1.98(a)(2), Applicant believes that copies of cited U.S. Patents and Published Applications are no longer required to be provided to the Office. Notification of this change was provided in the United States Patent and Trademark Office OG Notices dated October 12, 2004. Thus, Applicant has not included copies of any US Patents or Published Applications cited with this submission. Should the Office require copies to be provided, Applicant respectfully requests that notice of such requirement be directed to Applicant's belowsigned representative. Applicant acknowledges the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).

The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

SCOTT S. GRAVES ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938

Minneapolis, MN 55402

(612) 373-6959

KAUXSIK

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being filed using the USPTO's electronic filing system EFS-Web, and is addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexendria, VA 22313-1450 on this day of August 2006.

Substitute for form 1449A/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
Use as many sheets as necessary)

Sheet 1 of 1

Inder the Paperwork Reduction Act of 1995, no persons are	required to respond to a collection of information unless it contains a valid OMB control number
Complete if Known	
Application Number	10/787,067
Filing Date	February 25, 2004
First Named Inventor	Graves, Scott
Group Art Unit	1643
Examiner Name	Blanchard, David
Attorney Docket No: 2	295.061US4

US PATENT DOCUMENTS							
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate			
	US-5,714,350	02/03/1998	Co, M. S., et al.	01/13/1995			
	US-5,856,106	01/05/1999	Awwad, M. G., et al.	11/01/1995			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T²			
	WO-93/19196A1	09/30/1993	Bolt, S. L., et al.				

	OTHE	R DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		GOLDENBERG, D. M., "New Developments in Monoclonal Antibodies for Cancer Detection and Therapy", CA: A Cancer Journal for Clinicians, 44(1), (1994), 43-64	
		WEITZHANDLER, M., et al., "Analysis of Carbohydrates on IgG Preparations", Journal of Pharmaceutical Sciences 83(12), (December, 1994), 1670-1675	

EXAMINER DATE CONSIDERED